---
title: "Berry Genomics Co.,Ltd (000710.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000710.SZ.md"
symbol: "000710.SZ"
name: "Berry Genomics Co.,Ltd"
industry: "Biotechnology"
datetime: "2026-03-13T11:51:31.595Z"
locales:
  - [en](https://longbridge.com/en/quote/000710.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000710.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000710.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000710.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000710.SZ.md)


# Berry Genomics Co.,Ltd (000710.SZ)

## Company Overview

Berry Genomics Co.,Ltd, a genomics and  life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.berrygenomics.com](https://www.berrygenomics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:13.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 80 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.09% |  |
| Net Profit YoY | 9.39% |  |
| P/B Ratio | 2.51 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4060081398.90 |  |
| Revenue | 941541332.47 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -14.62% | E |
| Profit Margin | -27.13% | E |
| Gross Margin | 49.02% | B |
| Revenue YoY | -15.09% | E |
| Net Profit YoY | 9.39% | C |
| Total Assets YoY | -7.71% | E |
| Net Assets YoY | -13.56% | E |
| Cash Flow Margin | -368.54% | D |
| OCF YoY | -15.09% | E |
| Turnover | 0.39 | C |
| Gearing Ratio | 29.63% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Berry Genomics Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.09%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "9.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4060081398.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "941541332.47",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-14.62%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-27.13%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "49.02%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.09%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "9.39%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.71%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-13.56%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-368.54%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-15.09%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.39",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "29.63%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.89 | 48/80 | - | - | - |
| PB | 2.51 | 37/80 | 3.04 | 2.79 | 2.58 |
| PS (TTM) | 4.31 | 13/80 | 5.09 | 4.71 | 4.39 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 02 | RemeGen (688331.SH) | A | A | E | A | B | B |
| 03 | Gan & Lee (603087.SH) | B | B | D | A | B | B |
| 04 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | E | A | B | B |
| 05 | BTBP (600161.SH) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2021-10-25T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.35 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000710.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000710.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000710.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000710.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**